A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

May 26, 2026

Study Completion Date

December 26, 2028

Conditions
Glycogen Storage Disease
Interventions
DRUG

mRNA-3745

Sterile frozen liquid dispersion for injection

Trial Locations (16)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

27713

RECRUITING

Duke University Medical Center, Durham

28026

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

29011

RECRUITING

Hospital Regional Universitario de Malaga, Málaga

37000

RECRUITING

CHRU Tours - Hopital Clocheville, Tours

45229

TERMINATED

Cincinnati Children's Hospital Medical Center, Cincinnati

77030

RECRUITING

Baylor College of Medicine, Houston

92140

RECRUITING

AP-HP - Hôpital Antoine Béclère, Clamart

06030-0001

RECRUITING

University of Connecticut Health Center, Farmington

02115

TERMINATED

Boston Children's Hospital, Boston

77030-1501

RECRUITING

The University of Texas Health Science Center at Houston, Houston

84132-0001

RECRUITING

University of Utah, Salt Lake City

T6G 2R7

RECRUITING

Stollery Children's Hospital University of Alberta, Edmonton

M5G 1X8

RECRUITING

The Hospital for Sick Children, Toronto

9713 GZ

RECRUITING

Universitair Medisch Centrum Groningen, Groningen

04-730

RECRUITING

Instytut Pomnik Centrum Zdrowia Dziecka, Warsaw

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY